The ZEPHIR trial investigated PET imaging with [89Zr]Zr-DFO-trastuzumab to predict response to treatment with trastuzumab emtansine (T-DM1) in patients with HER2-positive BC.26 Here, ERBB2 is linked to breast cancer.